The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials.
Blackhall, Fiona H
Lee, Siow Ming
Lorigan, Paul C
Shepherd, F A
AffiliationPrincess Margaret Hospital/University Health Network, Toronto, Ontario, Canada.
MetadataShow full item record
AbstractBACKGROUND: Some non-small-cell lung cancer (NSCLC) surgical series have indicated that the positive prognostic effect of female sex is limited to patients with adenocarcinoma. We carried out a retrospective analysis to investigate the role of sex and histology on efficacy, toxicity, and dose delivery after chemotherapy. Patient and methods: Individual patient data were pooled from five randomized, phase III, advanced NSCLC chemotherapy trials. Primary outcomes were response rate, overall survival (OS), toxicity, and dose delivery. A secondary analysis examined survival by sex in histological subgroups. RESULTS: Of 2349 patients, 34% were women. Women had a higher response rate to chemotherapy (42% versus 40%, P = 0.01) and longer survival than men (median OS 9.6 versus 8.6 months, P = 0.002). The difference in OS remained after adjusting for age, stage, performance status, and histology (hazard ratio 0.83, 95% confidence interval 0.74-0.92, P = 0.0005). Upon further examination, longer survival in women was only seen in patients with adenocarcinoma (test for interaction P = 0.006). There were no differences in hematological toxicity or transfusions. Women experienced more grade 3-4 emesis than men (P < 0.0001) and more dose delays (P = 0.02) or dose reductions (P < 0.0001). CONCLUSION: The positive prognostic effect among women is confirmed in patients receiving platinum-based chemotherapy but appears confined to those with adenocarcinoma histology.
CitationThe influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. 2010:Ann Oncol
JournalAnnals of Oncology
- The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials.
- Authors: Wheatley-Price P, Le Maître A, Ding K, Leighl N, Hirsh V, Seymour L, Bezjak A, Shepherd FA, NCIC Clinical Trials Group.
- Issue date: 2010 May
- Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
- Authors: Yang ZY, Liu L, Mao C, Wu XY, Huang YF, Hu XF, Tang JL
- Issue date: 2014 Nov 17
- Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
- Authors: Rossi A, Chiodini P, Sun JM, O'Brien ME, von Plessen C, Barata F, Park K, Popat S, Bergman B, Parente B, Gallo C, Gridelli C, Perrone F, Di Maio M
- Issue date: 2014 Oct
- Chemotherapy for advanced non-small cell lung cancer in the elderly population.
- Authors: Santos FN, de Castria TB, Cruz MR, Riera R
- Issue date: 2015 Oct 20
- First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
- Authors: Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA
- Issue date: 2016 May 25